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a  b  s  t  r  a  c  t
INTRODUCTION  AND  IMPORTANCE:  Chylothorax  is an  uncommon  form  of pleural  effusion  characterized
by  the  presence  of  chylomicrons,  triglycerides  and  cholesterol  in  the  physical  and  chemical  examination
of the pleural  fluid.  It may  have  poor  prognosis  if  not  properly  treated.  Currently,  conservative  measures
are  the  first  line  of  treatment  for managing  chylothorax.  The  aim  of our study  is to show  and  suggest
the  use  of  octreotide  in association  with  talc  poudrage  as  good  option  to  manage  post-operative  a severe
chylothorax.
CASE  PRESENTATION:  A  59-year-old  male patient  who  underwent  a  replacement  of  the  ascending  aorta,
aortic hemiarch  and  surgery  of  the aortic  valve  for aortic  dissection  showed  a  severe  pleural  effusion
three  months  after  surgery.  Because  the  physical  and  chemical  examination  of  the pleural  fluid  revealed
high  levels  of  triglycerides  and  cholesterol,  a  conservative  treatment  with  pleural  drainage,  TPN  and  nihil
per os  was  attempted,  with  the introduction  of 0.3  mg/die  of  octreotide  on  day  thirty-four.  With the
application  of  talc  poudrage,  the  chylothorax  completely  resolved.
CLINICAL  DISCUSSION:  Octreotide  has  been  shown  to significantly  decrease  chylous  effusion  in  many
studies,  but  the  dose  and  duration  of therapy  have  not  yet  been  defined.  Our patient  responded  partially
to  octreotide  after  two  days  of  treatment,  with  the drainage  leak  reduced  to  less  than  100  mL/day.
CONCLUSION:  After  octreotide  treatment  associated  with  talc  poudrage,  the  drainage  leak  was  drastically
reduced,  suggesting  that this  could  be a useful  approach  in the  management  of severe  chylous  leaks.
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1. Introduction
Chylothorax is a rare form of pleural effusion characterized by
the accumulation of chyle in the pleural cavity due to the obstruc-
tion or disruption of lymphatic vessels, in particular the thoracic
duct or its main tributaries [1–4]. Bartolet described it for the first
time in 1633 [2]. It has poor prognosis if not treated appropriately,
with mortality rates of up to 75% [3–6].
The thoracic duct transports about 70% of ingested fat to the
blood stream. Chyle fat concentration is about 0.4–0.6 g/dl, and
it contains proteins, white blood cells, coagulation factors, elec-
trolytes and water [4].
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Low-volume chylothorax is often silent, whereas a high-volume
r rapidly occurring chylous effusion is characterized by cough,
yspnea and chest pain [3].
The standard criterion for diagnosing chylous effusion is the
resence of chylomicrons in the lipoprotein electrophoresis of the
leural fluid [1,2]. Originally, in clinical practice the diagnosis of
hylothorax was based on a milky appearance of pleural fluid,
lthough this characteristic frequently could not be observed – for
xample because of malnutrition [2].
Today we use simpler diagnostic criteria based on levels of pleu-
al triglycerides greater than 110 mg/dl, a ratio of pleural fluid
holesterol to pleural fluid triglycerides lower than 1.0 and a ratio
f pleural fluid triglycerides to serum triglycerides greater than
.0 [1,2,4]. Moreover, triglyceride levels lower than 50 mg/dl may
ule out a diagnosis of chylothorax (with a 5% chance of error)
2–4]. In chylothorax, cholesterol level is lower than 200 mg/dl;
n pseudochylothorax, cholesterol is greater than 200 mg/dl and
riglycerides are less than 110 mg/dl.Chylothorax can have traumatic, non-traumatic or idiopathic
auses [1–3]. Traumatic chyle effusions usually occur after cardiac
urgery (incidence of 0.3%–1.5%), after thoracic surgery (incidence
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Table  1
Physical and chemical examination of pleural fluid.
Day 0 Day 22 Day 26 Day 29 Day 42
Triglycerides (mg/dl) 1722 40 26 135 71
Cholesterol (mg/dl) 81 44 6 40 74



















































Proteins (g/l) 52 30 4 20 34
Specific gravity 1038 1024 1004 1018 1026
of 0.5%–1%), after abdominal aortic aneurism repair, because of
direct injury to lymphatic vessels [1–3].
Non-traumatic chylothorax is commonly caused by infiltration
of lymphatic ducts due to a malignant disease such as lym-
phoma, lymphoproliferative disorders or a metastatic carcinoma;
other possible causes are congenital anomalies, protein-losing
enteropathy, tuberculosis, thoracic duct thrombosis, amyloidosis,
hepatic cirrhosis, radiation injury and hypercoagulability [1,2].
Chylous effusion may  also be exudative (the majority) or tran-
sudative (about 25% of cases) [2,3,6]. Malnutrition, dehydration
and immunological impairment such as loss of lymphocytes and
antibodies, of loss of proteins and coagulation factors are typical
complications of this affliction. For these reasons, patients are often
in poor general conditions [3,5].
Conservative measures such as pleural drainage, a medium-
chain triglyceride (MCT) diet, total parenteral nutrition (TPN) and
nihil per os, subcutaneous injection of octreotide and chemical
pleurodesis are recommended as the first line of treatment and
are successful in 20%–80% of cases [1,3–5]. Video-assisted tho-
racoscopic (VATS) thoracic duct ligation is considered the first
surgical approach if the conservative approach fails, followed by
open surgery treatment. In case of failure, a pleuro-peritoneal shunt
should be performed [4,5,7,8]. After the failure of surgery, interven-
tional radiological treatment such as thoracic duct embolization
can be considered [3].
In the literature, octreotide has been shown to be a successful
treatment for the management of chylothorax [4,9–13].
In our study, this treatment was not completely successful with
a persistence of moderate pleural effusion. The aim of this clinical
case is to suggest the use of subcutaneous octreotide associated
with pleurodesis with talc poudrage to manage a severe post-
operative chylous leak. In summary, in our clinical case report, we
would like to show and describe how a chylothorax, after a car-
diothoracic operation, may  be treated and solve trying to avoid
as much as possible a new surgical approach. This work has been
reported in line with SCARE criteria [14].
2. Case presentation
A 59-year-old male patient with history of right partial nephrec-
tomy, left hemicolectomy and following adjuvant chemotherapy
for bowel cancer, underwent replacement of the ascending aorta,
aortic hemiarch and surgery of the aortic valve in November 2019
for aortic dissection. Family history was negative for drug assump-
tions and for any relevant genetic information or psychosocial
disorder.
After three months, because of dyspnea and shortness of breath,
a chest radiograph was taken and it revealed an abundant left pleu-
ral effusion (Fig. 1A). A pneumologist performed a thoracentesis
which showed chylous fluid, then the patient underwent left chest
drain insertion by a thoracic surgeon of our team and exhibited
a chyle leak of over 1500 mL.  Physical and chemical examination
of the drainage showed the fluid had an exudative nature (LDH:
261U/l, proteins: 52 g/l, specific gravity: 1038); the triglycerides
level was 1722 mg/dl; the cholesterol level was 81 mg/dl. The cul-
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A conservative treatment with an MCT  diet was  attempted. Due
o a chylous leak of more than 700 mL/day and a high triglycerides
evel (1186 mg/dl on day three, 365 mg/dl on day five), on post-
perative day six we placed a central vein catheter and TPN and
othing by mouth.
On post-operative day twenty-two, because the leak was  under
00 mL/day, we tried to reintroduce an MCT diet by mouth and
educe TPN. The triglycerides and cholesterol levels in the drainage
ecreased to 40 mg/dl and 44 mg/dl, respectively; the total proteins
rom the physical and chemical examination were 30 g/l; the LDH
evel was 771 U/l; the specific gravity 1024 (Table 1).
On day twenty-six, because the drainage was under 300 mL/day,
e  further reduced the TPN and restored a free diet. The triglyc-
rides and cholesterol level of the drainage decreased to 26 mg/dl
nd 6 mg/dl, respectively, with proteins level of 4 g/l, LDH level
f 216 U/l, specific gravity of 1004 and percentage of granulocyte
eutrophils of about 50% (Table 1). Because the drainage was about
50 mL/day, on day twenty-eight we  performed pleurodesis with
alc poudrage with a good tolerability and no consequences for the
atient and we stopped TPN on the following day. Physical and
hemical examination of the drainage showed the triglycerides
nd cholesterol level had increased to 135 mg/dl and 40 mg/dl,
espectively (Table 1).
On day thirty-four, as drainage was  still about 400 mL/day and
id not seem to be decreasing, we performed subcutaneous injec-
ion of octreotide (0.3 mg/day) and instituted an MCT  diet. After 2
ays, the drainage decreased significantly to less than 100 mL/day.
he chest radiograph showed an almost complete resolution of the
eft pleural effusion.
After a second chemical pleurodesis was performed on day forty
y our team with no complications, we noted no drainage leak, and
he levels of triglycerides had decreased to 71 mg/dl and cholesterol
ad increased to74 mg/dl, so we  stopped the octreotide injections
n day 42. The chest tube was removed on day 48 and the patient
as  discharged (Fig. 1B).
Five days after discharge, the patient was  admitted for hypoxic
espiratory failure with hypocapnia. Because a chest radiograph
evealed left pleural effusion, a thoracentesis was performed, with
eak of 1300 mL  of opalescent fluid. Physical and chemical exami-
ation of the fluid showed a granulocyte neutrophil percentage of
4.7%; the cultural and cytological examination were both nega-
ive. The patient underwent a left chest drain insertion, resulting
n a fluid leak of more than 2000 mL.  In the physical and chem-
cal examination of pleural fluid, we  noted that the triglycerides
nd cholesterol level were 21 mg/dl and 17 mg/dl, respectively.
Table 1, Fig. 2).
After a chest tomography was successively performed, we  noted
 4.4 × 2.2 cm subcarinal lymph node, on which Endobronchial
ltrasound Transbronchial Needle Aspiration (EBUS-TBNA) was
erformed; its cytological examination was negative.
Six days after the chest drain placement, the drainage decreased
ignificantly, and the chest radiograph showed almost a complete
esolution of the left pleural effusion, so the tube was removed, and
he patient was discharged. For the fact that chylothorax derived
rom a benign origin, patient perspectives were good and confirmed
y the chest x-ray performed after three months from the dis-
harge, showing a stable condition without pleural effusion (Fig. 3).
. DiscussionChylothorax is a rare complication of cardiac surgery that is
haracterized by lymphatic vessel injury and an accumulation of
hyle in the pleural cavity. It typically occurs in pediatric surgery,
ut it occurs even in adult patients [8,9].
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Fig. 1. A. Chest radiograph at admission. B. Chest radiograph at discharge after talc poudrage in association with subcutaneous octreotide.












rax  at physical and chemical examination.
Conservative measures, such as adequate hydration, an MCT
diet, TPN, thoracentesis, pleural drainage, pleurodesis and treat-
ment with octreotide are recommended as a first line of treatment,
and these are successful in 20%–80% of cases [1,3–5].
If a conservative approach fails and chylous drainage persists,
VATS surgery is required, followed by open surgery treatment in
case of failure [4,5,8]. Surgical treatments are thoracic duct liga-
tion or pleuro-peritoneal shunt in case of failure of the first surgery
[3–5,8].
After the failure of surgical procedures, interventional radiologi-
cal treatment such as thoracic duct embolization may  be attempted,
and this is successful in 70% of patients [3].
Octreotide is a long-acting somatostatin analog that increases
splanchnic arteriolar resistance and reduces gastrointestinal blood
flow. It may  increase blood glucose levels, so glycaemia should be




158f  the pleural effusion.
Many authors have demonstrated that conservative treatment
or 48 h with octreotide reduced drain output and led to a com-
lete resolution of chylous effusion [4,10–13]. Gabbieri et al. [12]
ecommended the early use of octreotide to reduce a chylous leak.
ctreotide treatment should be instituted for 1 week before surgery
s considered [1]. A surgical approach is indicated when the drain
utput is greater tham 1000 mL/day after 1–2 weeks of treatment
12].
In our case, we  attempted an MCT  diet after chest drain insertion.
ecause the pleural leak was above 700 mL/day and the triglyceride
evel was  above 110 mg/dl, we  started TPN and nihil per os.
After 16 days, with a progressive decrease in draiage leak, we
ried to reduce TPN and reintroduce an MCT  diet. Because of the
rogressive decreasing of the chylous leak to less than 250 mL/day,
e performed talc poudrage and stopped TPN on day 28, restoring
 free diet.
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Because triglyceride levels increased to 135 mg/dl and the
drainage leak was over 400 mL/day, on day 34 we started 300
mcg/day subcutaneous octreotide and instituted an MCT  diet, with
a significant reduction in and complete resolution of the chy-
lous leak after 2 days of treatment and a second talc poudrage.
Octreotide injections were suspended after 8 days. The triglyceride
level was 71 mg/dl.
Five days after discharge, the patient was admitted for relapsed
pleural effusion. Physical and chemical examination of the pleural
fluid showed that it was characterized by a triglyceride level of 21
mg/mL, demonstrating the non-chylous nature of the pleural fluid.
Thus, our patient responded to octreotide therapy within two
days of treatment and to chemical pleurodesis with complete res-
olution of chylothorax. Injections were suspended after 8 days and
no further conservative or surgical approaches were required – as
has already been shown by many authors [4,10–13].
4. Conclusions
Pharmacological treatment using octreotide – a long-acting
somatostatin analog – has been shown to significantly decrease
chyle output in many studies [1,4,5,10–12], even though the dose
and duration of this therapy has yet to be defined [1,5]. Manasvini
et al. [1] noted that in retrospective studies, the consensus view
was to institute octreotide therapy for 1 week before considering a
surgical approach. Treatment is considered successful when drain
output decreases significantly within 48–72 hours [3,7].
Our patient responded partially to octreotide injections within
2 days of treatment, with a drainage leak of less than 100 mL/day.
The association of talc poudrage to the octreotide treatment signif-
icantly reduced fluid leak to zero.
In our case report, we suggested that the use of octreotide in
association with talc poudrage may  be useful in the management of
severe chylous leaks that are refractory to conservative treatment
with an MCT  diet or TPN and nihil per os.
Patient was  very satisfied to avoid eventual surgical approach
and to solve the pleural effusion with a medical treatment, espe-
cially for the fact that he was recently underwent to a cardiothoracic
operation.
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